Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 7/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705972 | 0.97 | ENPEP (0.54) | ENPEPFOLH1 | |
| SCHEMBL29705999 | 0.97 | ENPEP (0.54) | ENPEPFOLH1 | |
| SCHEMBL29934217 | 0.96 | ENPEP (0.50) | ENPEPFOLH1F2CPB2GRIN2D | |
| SCHEMBL29603899 | 0.96 | ENPEP (0.51) | ENPEPFOLH1F2GRIN2DGRIN3B | |
| SCHEMBL29455891 | 0.96 | ENPEP (0.51) | ENPEPFOLH1F2GRIN2DGRIN3B | |
| SCHEMBL23230150 | 0.96 | ENPEP (0.51) | ENPEPFOLH1F2GRIN2DGRIN3B | |
| SCHEMBL29603233 | 0.96 | ENPEP (0.51) | ENPEPFOLH1F2GRIN2DGRIN3B | |
| SCHEMBL30118956 | 0.94 | FOLH1 (0.59) | ENPEPFOLH1CPB2 | |
| SCHEMBL30118962 | 0.94 | ENPEP (0.49) | ENPEPFOLH1F2GRIN2DGRIN3B | |
| SCHEMBL23230086 | 0.93 | ENPEP (0.47) | ENPEPFOLH1F2GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116551-B1 | STERILIZATION OF PEPTIDE COMPOSITIONS | 3 D MATRIX LTD (JP) | 2022-09-07 | — | — | EP | claimed |
| US-12629446-B2 | Vascular embolic system | 3-D MATRIX, LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260116919-A1 | SELF-ASSEMBLING PEPTIDE COMPOSITIONS | 3-D MATRIX, LTD. (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20250311587-A1 | VASCULAR EMBOLIC SYSTEM | 3-D MATRIX, LTD. (JP) | 2025-10-02 | — | — | US | disclosed |
| US-12377196-B2 | Preventing biological tissue adhesion | 3-D MATRIX, LTD. (JP) | 2025-08-05 | — | — | US | disclosed |
| US-20250177614-A1 | PREVENTING BIOLOGICAL TISSUE ADHESION | 3-D MATRIX, LTD. (JP) | 2025-06-05 | — | — | US | disclosed |
| EP-3628337-B1 | STERILIZATION AND FILTRATION OF PEPTIDE COMPOSITIONS | 3 D MATRIX LTD (JP) | 2025-05-28 | — | — | EP | disclosed |
| US-12115264-B2 | Sterilization and filtration of peptide compositions | 3-D MATRIX, LTD. (JP) | 2024-10-15 | — | — | US | disclosed |
| CN-117138022-A | Self-assembling peptide compositions | 三维矩阵有限责任公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230241294-A1 | PREVENTING BIOLOGICAL TISSUE ADHESION | 3-D MATRIX, LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| EP-3116551-B1 | STERILIZATION OF PEPTIDE COMPOSITIONS | 3 D MATRIX LTD (JP) | 2022-09-07 | — | — | EP | disclosed |
| US-20220168462-A1 | VASCULAR EMBOLIC SYSTEM | 3-D MATRIX, LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220160939-A1 | SELF-ASSEMBLING PEPTIDES AS BRONCHIAL OBSTRUCTION AGENTS | 3-D MATRIX, LTD. (JP) | 2022-05-26 | — | — | US | disclosed |
| US-20220111126-A1 | PREVENTING BIOLOGICAL TISSUE ADHESION | 3-D MATRIX, LTD. (JP) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116919-A1 | SELF-ASSEMBLING PEPTIDE COMPOSITIONS | CALCA, MCM6, MYL6 | ENPEP 3612/4885FOLH1 2549/4885F2 3537/4885 |
| US-12629446-B2 | Vascular embolic system | TNNI3, MYLK, ADM2 | ENPEP 757/4885FOLH1 1444/4885F2 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.